News GSK preps filings for chronic hepatitis B drug bepirovirsen GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.
News Amgen inks $840m takeover of UK's Dark Blue Therapeutics Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.
News Lilly taps Nimbus for another obesity candidate For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.
News Alumis shoots up as its Sotyktu rival aces psoriasis trials Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.
News RNA specialist Ribo files $205m IPO in Hong Kong Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.
News Aktis Oncology files much-expanded IPO Aktis Oncology has filed its IPO, seeking to raise up to around $210 million in what could be the first biotech listing on the Nasdaq in 2026.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.